# Phase 3 Nasopharyngeal Carcinoma trials: 53 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 53 trials in phase 3 for Nasopharyngeal Carcinoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 Nasopharyngeal Carcinoma trials: 53 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/nasopharyngeal-carcinoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 53
- Recruiting or not yet: 53
- Read on: November 19, 2026

## Trials

The 25 newest of 53, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07925021 | A Study of SYS6010 Combined With Enlonstobart in Patients With Previously Systemic Treatment-Naive R/M Nasopharyngeal Carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 | Recruiting | Previously Systemic Treatment-Naive Recurrent or Metastatic Nasopharyngeal Carcinoma | 424 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925021) |
| September 1, 2026 | NCT07796789 | Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma | Sun Yat-sen University | Phase 3 | Recruiting | Nasopharyngeal Cancinoma (NPC) | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07796789) |
| August 24, 2026 | NCT07783321 | A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the... | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Nasopharyngeal Carcinoma (NPC) | 404 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783321) |
| July 16, 2026 | NCT07706985 | Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course... | Sun Yat-sen University | Phase 3 | Recruiting | Nasopharyngeal Carcinoma (NPC) | 566 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07706985) |
| May 15, 2026 | NCT07590024 | RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 3 | Recruiting | Nasopharyngeal Carcinoma (NPC) | 651 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07590024) |
| April 20, 2026 | NCT07540390 | GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC. | Sun Yat-sen University | Phase 3 | Not yet recruiting | Nasopharyngeal Carcinoma | 442 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07540390) |
| March 9, 2026 | NCT07459296 | Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC | First Affiliated Hospital of Guangxi Medical University | Phase 3 | Recruiting | Nasopharyngeal Carcinoma (NPC) | 266 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07459296) |
| January 14, 2026 | NCT07340515 | Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial | Sponsor not shown (see the record) | Phase 3 | Recruiting | Nasopharyngeal Carcinoma (NPC) | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07340515) |
| January 9, 2026 | NCT07328854 | 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma | Sponsor not shown (see the record) | Phase 3 | Recruiting | Nasopharyngeal Carcinoma | 346 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07328854) |
| January 9, 2026 | NCT07328841 | Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission... | Sponsor not shown (see the record) | Phase 3 | Recruiting | Nasopharyngeal Carcinoma (NPC) | 456 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07328841) |
| January 8, 2026 | NCT07327216 | Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma | Affiliated Hospital of Guangdong Medical University | Phase 3 | Recruiting | Nasopharyngeal Carcinoma (NPC) | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07327216) |
| December 24, 2025 | NCT07303023 | Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC | Fudan University | Phase 3 | Recruiting | Nasopharyngeal Carcinoma (NPC) | 462 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07303023) |
| September 23, 2025 | NCT07188584 | Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer | Sponsor not shown (see the record) | Phase 3 | Recruiting | Nasopharyngeal Carcinoma (NPC) | 166 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07188584) |
| July 18, 2025 | NCT07072000 | Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity | Sponsor not shown (see the record) | Phase 3 | Not yet recruiting | Nasopharyngeal Cancinoma (NPC) | 550 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07072000) |
| June 3, 2025 | NCT07000643 | Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma | Sponsor not shown (see the record) | Phase 3 | Recruiting | Nasopharyngeal Carcinoma | 386 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07000643) |
| May 16, 2025 | NCT06976190 | A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic... | Lepu Biopharma Co., Ltd. | Phase 3 | Recruiting | Recurrent or Metastatic Nasopharyngeal Carcinoma | 446 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06976190) |
| March 28, 2025 | NCT06900218 | PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma | Sun Yat-sen University | Phase 3 | Not yet recruiting | Nasopharyngeal Carcinoma (NPC) | 664 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06900218) |
| January 15, 2025 | NCT06775756 | Reducing Dose and Irradiated Volume in Cervical Prophylactic Irradiation for Nasopharyngeal Cancer | Fujian Cancer Hospital | Phase 3 | Not yet recruiting | Nasopharyngeal Carcinoma | 474 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06775756) |
| December 30, 2024 | NCT06752239 | Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC | Jiangxi Provincial Cancer Hospital | Phase 3 | Recruiting | Nasopharyngeal Carcinoma, Quality of Life, Thyroid Diseases, Radiotherapy Side Effect, Radiotherapy | 474 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06752239) |
| November 5, 2024 | NCT06675214 | Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction... | Sun Yat-sen University | Phase 3 | Recruiting | Nasopharyngeal Carcinoma, De-escalation Therapy | 586 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06675214) |
| July 23, 2024 | NCT06516133 | Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma | Sun Yat-sen University | Phase 3 | Recruiting | Nasopharyngeal Carcinoma | 494 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06516133) |
| June 3, 2024 | NCT06438627 | Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial | Sponsor not shown (see the record) | Phase 3 | Recruiting | Nasopharyngeal Carcinoma | 164 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06438627) |
| April 25, 2024 | NCT06383780 | Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis. | Sponsor not shown (see the record) | Phase 3 | Recruiting | Nasopharyngeal Carcinoma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06383780) |
| February 26, 2024 | NCT06277050 | Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma | Jiangxi Provincial Cancer Hospital | Phase 3 | Recruiting | Nasopharyngeal Carcinoma, High-Risk Cancer, Maintenance Therapy | 264 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06277050) |
| February 5, 2024 | NCT06241612 | Individualized Elective Neck Irradiation in NPC Patients | Sun Yat-sen University | Phase 3 | Recruiting | Nasopharyngeal Carcinoma | 470 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06241612) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Sun Yat-sen University | 22 |
| Fudan University | 4 |
| Eye & ENT Hospital of Fudan University | 3 |
| Fujian Cancer Hospital | 2 |
| Jiangxi Provincial Cancer Hospital | 2 |
| [CSPC Megalith Biopharmaceutical Co.,Ltd.](https://specstream.ai/data/clinical-trials/company/cspc-megalith-biopharmaceutical-co-ltd) | 1 |
| Affiliated Hospital of Guangdong Medical University | 1 |
| First Affiliated Hospital of Guangxi Medical University | 1 |
| Air Force Military Medical University, China | 1 |
| Lepu Biopharma Co., Ltd. | 1 |
| [CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.](https://specstream.ai/data/clinical-trials/company/cspc-zhongnuo-pharmaceutical-shijiazhuang-co-ltd) | 1 |
| Affiliated Cancer Hospital & Institute of Guangzhou Medical University | 1 |
| Cancer Hospital of Guangxi Medical University | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| Nanfang Hospital, Southern Medical University | 1 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 51 |
| Singapore | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Hot dog restaurants in the United States](https://specstream.ai/data/businesses/hot-dog-restaurants/united-states)
- [Stone and masonry companies in the United States](https://specstream.ai/data/businesses/stone-and-masonry-companies/united-states)
- [Cuban restaurants in the United States](https://specstream.ai/data/businesses/cuban-restaurants/united-states)
- [Optical wholesalers in the United States](https://specstream.ai/data/businesses/optical-wholesalers/united-states)
- [Asian restaurants in the United States](https://specstream.ai/data/businesses/asian-restaurants/united-states)
- [Hardware and fastener manufacturers in the United States](https://specstream.ai/data/businesses/hardware-and-fastener-manufacturers/united-states)
